FIELD: biochemistry.
SUBSTANCE: present invention relates to new compounds of Formula (II), Y, R1, R2 are given in the claims.
EFFECT: compounds of the invention are intended for use in treatment of diseases mediated by GPR119.
27 cl, 2 tbl, 37 ex
Title | Year | Author | Number |
---|---|---|---|
HETEROCYCLIC SUBSTANCES-GPR119 AGONISTS | 2017 |
|
RU2734500C2 |
PYRUVATEKINASE MODULATORS AND THEIR USE | 2018 |
|
RU2797518C2 |
THIAZOLPYRIMIDINES | 2012 |
|
RU2610840C2 |
PIPERIDINYLPYRAZOLOPYRIMIDINONES AND USE THEREOF | 2015 |
|
RU2713937C2 |
TREATMENT METHOD | 2012 |
|
RU2621148C2 |
USE OF 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | 2017 |
|
RU2759380C2 |
POLYCYCLIC COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF POLYPEPTIDES OF FAST ACCELERATED FIBROSARCOMA | 2019 |
|
RU2830173C2 |
NEW OXADIAZOLES | 2019 |
|
RU2805208C2 |
PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | 2009 |
|
RU2561104C2 |
Authors
Dates
2021-06-04—Published
2017-04-05—Filed